Capital International Sarl Acquires 24,055 Shares of Illumina, Inc. $ILMN

Capital International Sarl raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 24.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 120,752 shares of the life sciences company’s stock after purchasing an additional 24,055 shares during the period. Capital International Sarl’s holdings in Illumina were worth $11,468,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Parkside Financial Bank & Trust lifted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC bought a new stake in shares of Illumina in the 3rd quarter worth about $29,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Illumina in the third quarter worth approximately $33,000. Mather Group LLC. bought a new stake in shares of Illumina during the third quarter worth $46,000. Finally, Evelyn Partners Investment Management LLP increased its stake in Illumina by 4,927.3% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after buying an additional 542 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.3%

Illumina stock opened at $124.28 on Tuesday. The stock has a market cap of $19.00 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 2.38 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The stock has a 50-day moving average of $134.17 and a two-hundred day moving average of $119.55. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several research reports. Guggenheim upped their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Stifel Nicolaus increased their target price on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. JPMorgan Chase & Co. cut their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Finally, Robert W. Baird set a $137.00 price objective on shares of Illumina in a report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.